Astellas Pharma Exercises Option to License AI-Designed AAV Capsid for Muscle-Targeted Gene Therapy from Dyno Therapeutics

Apr 09, 2026 11:24 CST Updated 11:24

Dyno Therapeutics

Developer of Artificial Intelligence Gene Therapy Platform

Abstract：Astellas Deepens Collaboration with Dyno Therapeutics, Secures License for AAV Capsid Designed for Skeletal Muscle Delivery through a $15 Million Option Agreement. This AI-optimized gene therapy vector aims to address the core challenge of gene delivery in muscle diseases, with Astellas taking full responsibility for subsequent clinical development and commercialization. Notably, Dyno Therapeutics also holds a collaboration with Roche exceeding $1 billion, establishing itself as a silent winner in the gene delivery field.

15 Million Hammered Down, Five Years of Cooperation Finally Bear Fruit

On April 8, Astellas announced the new progress of its collaboration with Dyno Therapeutics, Inc. The announcement was not high-profile, but it contained key moves in the field of gene therapy.

The collaboration between the two parties began as early as 2021, when Astellas paid $18 million upfront and promised up to $1.6 billion in milestone payments and royalties, solely for the joint development of AAV vectors. Now, this partnership has finally achieved substantial progress — Astellas has decided to license an AAV capsid developed by Dyno Therapeutics specifically for gene therapy in muscle diseases, paying $15 million for it. If future milestones are met, Dyno could receive additional earnings.

To be honest, such a cooperation model is actually quite common in the field of gene therapy. Big pharmaceutical companies provide money and resources, while biotech companies contribute technology and innovation, each playing to their strengths. This case is no exception. Once this capsid is used to develop a drug candidate, the subsequent preclinical research, clinical trials, and eventual commercial promotion will all be shouldered by Astellas, while Dyno Therapeutics will focus on the technology itself.

This is also the first time Astellas has licensed a capsid asset from Dyno Therapeutics, Inc., after five years of effort, demonstrating its high expectations for this muscle-targeting vector.

AI-Modified Capsid Cracks the Muscle Delivery Dilemma

Astellas is willing to spend real money, and the core reason is being impressed by the strength of this AAV capsid.

Speaking of which, the AAV capsid, though seemingly unremarkable, is the "key courier" in gene therapy — a tiny protein shell that encapsulates viral single-stranded DNA, with a diameter of only about 25 nanometers. Though inconspicuous, it can precisely bind to cells and deliver therapeutic genes, making it the most mainstream gene delivery vector in the industry today. However, gene therapy for muscle diseases has hit a snag precisely at this "delivery" step.

Dyno Therapeutics' CEO, Dr. Eric Kelsic, confided in the media before the official announcement: "Delivering therapeutic genes to all the muscle fibers in the body that need them is extremely challenging." In the past, pharmaceutical companies could only rely on high doses of vectors to make up for it, but with higher doses come not only skyrocketing costs but also safety risks, placing a heavier burden on patients. This has been an industry-wide conundrum for many years.

And Dyno's confidence comes from its own AI platform. They rely on AI to modify natural capsid shells and can track the destination of genetic material after delivery. "The modified capsid can reach more muscle cells with a lower dose, offering better efficacy and greater safety." Kelsic's words highlight the core advantage of this capsid and hit the nail on the head regarding Astellas' needs.

Backed by Two Titans, Dyno Bets on Gene Delivery

Dyno Therapeutics Being Valued by AstraZeneca Is No Coincidence. Behind this company stands another giant — Roche.

Beyond the collaboration with Astellas, Dyno's AAV partnership with Roche is more significant, with a potential total value exceeding $1 billion. It was initiated as early as 2020, focusing on gene therapy for central nervous system and liver diseases. In January 2025, Roche had already paid a $7 million upfront fee to secure an option for a novel capsid, demonstrating strong recognition of Dyno's technology.

Kelsic also frankly stated that Astellas’ authorization is an affirmation of the company’s years of platform development. “AI can help us design the next generation of capsid proteins, optimizing them bit by bit to make their functions more complete.” In his view, this AI-driven, partner-centric model is the key to breakthroughs in gene therapy.

To a certain extent, Dyno Therapeutics has caught the wave of gene therapy. While partnering with Astellas to tackle muscle diseases, it is also collaborating with Roche to advance in the central nervous system and liver fields. Backed by resources from two industry giants and empowered by AI technology, the future seems promising.

However, the development of gene therapy has never been smooth sailing. Whether this AI-modified capsid can truly break through the bottleneck of muscle delivery, and whether Astellas can rely on it to gain a foothold in the field of muscular diseases, remains uncertain. After all, translating the advantages observed in laboratory settings to clinical patients still has a long way to go.

Reference Source:https://www.fiercebiotech.com/biotech/astellas-pharma-and-dyno-therapeutics-unearth-15m-muscle-disorder-capsid-ongoing

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!

Please indicate: Name + Research Direction!

Edition

Authority

Sound

Bright

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and do not represent the position of this site.